| Literature DB >> 33613264 |
Yi Yao1, Yonggang Zhang2,3,4, Xiaoyang Liao1, Rong Yang1, Yi Lei1, Jianzhao Luo1.
Abstract
Stroke is the leading cause of global mortality and disability. Cerebral edema and intracranial hypertension are common complications of cerebral infarction and the major causes of mortality. The formation of cerebral edema includes three stages (cytotoxic edema, ionic edema, and vasogenic edema), which involve multiple proteins and ion channels. A range of therapeutic agents that successfully target cerebral edema have been developed in animal studies, some of which have been assessed in clinical trials. Herein, we review the mechanisms of cerebral edema and the research progress of anti-edema therapies for use after ischemic stroke.Entities:
Keywords: cerebral edema; clinical trial; drug therapy; ischemia stroke; molecular mechanism; preclinical drug evaluation
Year: 2021 PMID: 33613264 PMCID: PMC7890111 DOI: 10.3389/fnagi.2020.618819
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750